BioSpace News Archive

Aceragen, Inc., announced that the Company intends to voluntarily terminate the listing of its common stock on the Nasdaq Capital Market by filing a Form 25 with the Securities and Exchange Commission on or about August 15, 2023.

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of James Fairbairn as Chief Financial Officer to replace Amar Keshri who left the Company’s employ effective July 31, 2023.

INOVIO today announced that it has made equity grants to two newly hired employees under its 2022 Inducement Plan.

TheracosBio today announced the publication of a study titled “ Bexagliflozin as an Adjunct to Metformin for the Treatment of Type 2 Diabetes in Adults: a 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial ” in Diabetes, Obesity and Metabolism . The Phase 3 study assessed the safety and effectiveness of Brenzavvy™.

Adial Pharmaceuticals, Inc. announced that it will effect a 1-for-25 reverse stock split of its common stock, par value $0.001 per share, that will become effective on August 4, 2023 at 11:59 p.m. Eastern Time.

North America’s largest pure-play distributor of scientific and controlled environment products, Thomas Scientific, has completed the acquisition of Massachusetts -based cleanroom, safety, and industrial products provider Day Associates, Inc.

Avinger, Inc. announced the conversion of approximately 12% of its existing debt with entities affiliated with CRG Partners III L.P. into shares of a new series of convertible preferred stock.

Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will present at the SHARE Series event on Monday, August 14, 2023 at 8:30 AM Eastern time.

Viridian Therapeutics, Inc. announced that a majority of the independent directors serving on the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 140,000 shares of the Company’s common stock to two new employees on August 1, 2023.

NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the Company will host an Extraordinary General Meeting of Shareholders (“EGM”) on September 1st, 2023 at 02:00 pm CEST at its headquarters.